{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:22:22Z","timestamp":1763749342121,"version":"3.30.1"},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>Although T-cell malignancies are relatively less prevalent compared to B-cell malignancies,\nthey are highly malignant, and patients usually have poor prognoses. Employing CD7-targeted chimeric\nantigen receptor (CAR) T cell therapy as a novel immunotherapy to treat malignant T cells faces numerous challenges\nand is in its early phase. To evaluate this possibility, we aimed to review and meta-analyze the related\nclinical trials systematically.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>On October 9, 2023, the online databases of PubMed, Scopus, Embase, and Web of Science were systematically\nsearched for pertinent studies. After completing a two\u2010step title\/abstract and full-text screening process,\nthe eligible studies were included.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>We observed a pooled overall response rate (ORR) of 100%. Partial response (PR), stringent and\/or\ncomplete response (sCR\/CR), and relapse rate were 6%, 85%, and 18%, respectively. Additionally, the pooled\nrate of minimal residual disease (MRD) negativity was 85%. The most common grade \u22653 adverse events were\nrelated to hematological toxicities, including neutropenia (100%), thrombocytopenia (79%), and anemia (57%).\nCytokine release syndrome (CRS) was also a frequent complication with a 100% rate; however, 81% of CRS\nevents were low grades. No grade \u22653 GVHD was reported, and the immune effector cell\u2013associated neurotoxicity\nsyndrome (ICANS grade \u22653) was rare (4%).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>CD7 is an active and safe target that shows promising results in the treatment of relapsed and\/or\nrefractory (r\/r) T-cell malignancies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0118715206321313240820101412","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T06:13:56Z","timestamp":1724825636000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-7858","authenticated-orcid":true,"given":"Mohsen","family":"Dashti","sequence":"first","affiliation":[{"name":"Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":true,"given":"Mohammad Amin","family":"Habibi","sequence":"additional","affiliation":[{"name":"Clinical Research Development Center, Qom University of Medical Sciences, Qom, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8192-8542","authenticated-orcid":true,"given":"Negar","family":"Nejati","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Centre, Gene, Cell &amp; Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7366-0972","authenticated-orcid":true,"given":"Behrouz","family":"Robat-Jazi","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7908-0836","authenticated-orcid":true,"given":"Mahsa","family":"Ahmadpour","sequence":"additional","affiliation":[{"name":"Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-3189","authenticated-orcid":true,"given":"Negar","family":"Dokhani","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Research Center, Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-7824","authenticated-orcid":true,"given":"Aida Rezaei","family":"Nejad","sequence":"additional","affiliation":[{"name":"Stem Cell and Regenerative Medical Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6372-4994","authenticated-orcid":true,"given":"Shaghayegh","family":"Karami","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9315-5137","authenticated-orcid":true,"given":"Erfan","family":"Alinejad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Babol University of Medical Sciences, Babol, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5851-6531","authenticated-orcid":true,"given":"Amir H.","family":"Malekijoo","sequence":"additional","affiliation":[{"name":"Department of Computer Engineering, Semnan University, Semnan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-3552","authenticated-orcid":true,"given":"Afsaneh","family":"Ghasemzadeh","sequence":"additional","affiliation":[{"name":"Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-882X","authenticated-orcid":true,"given":"Farhad","family":"Jadidi-Niaragh","sequence":"additional","affiliation":[{"name":"Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"Teachey D.T.","year":"2019","unstructured":"Teachey D.T.; Pui C.H.; Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol  2019,20(3),e142-e154","journal-title":"Lancet Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Tan Y.","year":"2023","unstructured":"Tan Y.; Shan L.; Zhao L.; Deng B.; Ling Z.; Zhang Y.; Peng S.; Xu J.; Duan J.; Wang Z.; Yu X.; Zheng Q.; Xu X.; Tian Z.; Zhang Y.; Zhang J.; Chang A.H.; Feng X.; Pan J.; Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol  2023,16(1),34","journal-title":"J Hematol Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"Hunger S.P.","year":"2012","unstructured":"Hunger S.P.; Lu X.; Devidas M.; Camitta B.M.; Gaynon P.S.; Winick N.J.; Reaman G.H.; Carroll W.L.; Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol  2012,30(14),1663-1669","journal-title":"J Clin Oncol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3324\/haematol.2015.125583","volume":"100","author":"den Hoed MA.","year":"2015","unstructured":"den Hoed MA.; Pluijm SM.; te Winkel ML.; de Groot-Kruseman HA.; Fiocco M.; Hoogerbrugge P.; Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia. Haematologica  2015,100(12),1564","journal-title":"Haematologica"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","volume":"126","author":"Litzow M.R.","year":"2015","unstructured":"Litzow M.R.; Ferrando A.A.; How I treat T-cell acute lymphoblastic leukemia in adults. Blood  2015,126(7),833-841","journal-title":"Blood"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","volume":"14","author":"Bhojwani D.","year":"2013","unstructured":"Bhojwani D.; Pui C.H.; Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol  2013,14(6),e205-e217","journal-title":"Lancet Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43046-023-00176-1","volume":"35","author":"Ashry M.S.E.","year":"2023","unstructured":"Ashry M.S.E.; Radwan E.; Abdellateif M.S.; Arafah O.; Hassan N.M.; Clinical features, laboratory characteristics, and outcome of ETP and TCRA\/D aberrations in pediatric patients with T-acute lymphoblastic leukemia. J Egypt Natl Canc Inst  2023,35(1),17","journal-title":"J Egypt Natl Canc Inst"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"876758","DOI":"10.3389\/fonc.2022.876758","volume":"12","author":"Polg\u00e1rov\u00e1 K.","year":"2022","unstructured":"Polg\u00e1rov\u00e1 K.; Ot\u00e1hal P.; \u0160\u00e1lek C.; Pytl\u00edk R.; Chimeric antigen receptor based cellular therapy for treatment of T-cell malignancies. Front Oncol  2022,12,876758","journal-title":"Front Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1285406","DOI":"10.3389\/fimmu.2023.1285406","volume":"14","author":"Karsten H.","year":"2023","unstructured":"Karsten H.; Matrisch L.; Cichutek S.; Fiedler W.; Alsdorf W.; Block A.; Broadening the horizon: potential applications of CAR-T cells beyond current indications. Front Immunol  2023,14,1285406","journal-title":"Front Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221143025","volume":"13","author":"Luo L.","year":"2022","unstructured":"Luo L.; Zhou X.; Zhou L.; Liang Z.; Yang J.; Tu S.; Li Y.; Current state of CAR-T therapy for T-cell malignancies. Ther Adv Hematol  2022,13","journal-title":"Ther Adv Hematol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"Zhang X.","year":"2023","unstructured":"Zhang X.; Yang J.; Li J.; Qiu L.; Zhang J.; Lu Y.; Zhao Y.; Jin D.; Li J.; Lu P.; Analysis of 60 patients with relapsed or refractory T\u2010cell acute lymphoblastic leukemia and T\u2010cell lymphoblastic lymphoma treated with  \u2010targeted chimeric antigen receptor\u2010T cell therapy. Am J Hematol  2023,98(12),1898-1908","journal-title":"Am J Hematol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"Gomes-Silva D.","year":"2017","unstructured":"Gomes-Silva D.; Srinivasan M.; Sharma S.; Lee C.M.; Wagner D.L.; Davis T.H.; Rouce R.H.; Bao G.; Brenner M.K.; Mamonkin M.; CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood  2017,130(3),285-296","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"Cooper M.L.","year":"2018","unstructured":"Cooper M.L.; Choi J.; Staser K.; Ritchey J.K.; Devenport J.M.; Eckardt K.; Rettig M.P.; Wang B.; Eissenberg L.G.; Ghobadi A.; Gehrs L.N.; Prior J.L.; Achilefu S.; Miller C.A.; Fronick C.C.; O\u2019Neal J.; Gao F.; Weinstock D.M.; Gutierrez A.; Fulton R.S.; DiPersio J.F.; An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia  2018,32(9),1970-1983","journal-title":"Leukemia"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"Pan J.","year":"2021","unstructured":"Pan J.; Tan Y.; Wang G.; Deng B.; Ling Z.; Song W.; Seery S.; Zhang Y.; Peng S.; Xu J.; Duan J.; Wang Z.; Yu X.; Zheng Q.; Xu X.; Yuan Y.; Yan F.; Tian Z.; Tang K.; Zhang J.; Chang A.H.; Feng X.; Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: First-in-human, phase I trial. J Clin Oncol  2021,39(30),3340-3351","journal-title":"J Clin Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"Page M.J.","year":"2021","unstructured":"Page M.J.; McKenzie J.E.; Bossuyt P.M.; Boutron I.; Hoffmann T.C.; Mulrow C.D.; Shamseer L.; Tetzlaff J.M.; Akl E.A.; Brennan S.E.; Chou R.; Glanville J.; Grimshaw J.M.; Hr\u00f3bjartsson A.; Lalu M.M.; Li T.; Loder E.W.; Mayo-Wilson E.; McDonald S.; McGuinness L.A.; Stewart L.A.; Thomas J.; Tricco A.C.; Welch V.A.; Whiting P.; Moher D.; The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg  2021,88,105906","journal-title":"Int J Surg"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"Slim K.","year":"2003","unstructured":"Slim K.; Nini E.; Forestier D.; Kwiatkowski F.; Panis Y.; Chipponi J.; Methodological index for non\u2010randomized studies ( MINORS ): development and validation of a new instrument. ANZ J Surg  2003,73(9),712-716","journal-title":"ANZ J Surg"},{"year":"2011","key":"ref=17","unstructured":"Cochrane handbook for systematic reviews of interventions.  Available from:  https:\/\/handbook-5-1.cochrane.org\/(accessed on 31-7-2024)2011"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.omto.2022.02.013","volume":"24","author":"Ye J.","year":"2022","unstructured":"Ye J.; Jia Y.; Tuhin I.J.; Tan J.; Monty M.A.; Xu N.; Kang L.; Li M.; Lou X.; Zhou M.; Fang X.; Shao J.; Zhu H.; Yan Z.; Yu L.; Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Mol Ther Oncolytics  2022,24,719-728","journal-title":"Mol Ther Oncolytics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"Png Y.T.","year":"2017","unstructured":"Png Y.T.; Vinanica N.; Kamiya T.; Shimasaki N.; Coustan-Smith E.; Campana D.; Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv  2017,1(25),2348-2360","journal-title":"Blood Adv"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"blood.2021014498","DOI":"10.1182\/blood.2021014498","volume":"140","author":"Lu P.","year":"2022","unstructured":"Lu P.; Liu Y.; Yang J.; Zhang X.; Yang X.; Wang H.; Wang L.; Wang Q.; Jin D.; Li J.; Huang X.; Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood  2022,140(4),blood.2021014498","journal-title":"Blood"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"Chiesa R.","year":"2023","unstructured":"Chiesa R.; Georgiadis C.; Syed F.; Zhan H.; Etuk A.; Gkazi S.A.; Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med  2023,389(10),899-910","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"Watanabe N.","year":"2023","unstructured":"Watanabe N.; Mo F.; Zheng R.; Ma R.; Bray V.C.; van Leeuwen D.G.; Sritabal-Ramirez J.; Hu H.; Wang S.; Mehta B.; Srinivasan M.; Scherer L.D.; Zhang H.; Thakkar S.G.; Hill L.C.; Heslop H.E.; Cheng C.; Brenner M.K.; Mamonkin M.; Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther  2023,31(1),24-34","journal-title":"Mol Ther"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"Freiwan A.","year":"2022","unstructured":"Freiwan A.; Zoine J.T.; Crawford J.C.; Vaidya A.; Schattgen S.A.; Myers J.A.; Patil S.L.; Khanlari M.; Inaba H.; Klco J.M.; Mullighan C.G.; Krenciute G.; Chockley P.J.; Naik S.; Langfitt D.M.; Mamonkin M.; Obeng E.A.; Thomas P.G.; Gottschalk S.; Velasquez M.P.; Engineering naturally occurring CD7\u2212 T cells for the immunotherapy of hematological malignancies. Blood  2022,140(25),2684-2696","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/JCO.2020.38.15_suppl.3013","volume":"38","author":"Wang X.","year":"2020","unstructured":"Wang X.; Li S.; Gao L.; Yuan Z.; Wu K.; Liu L.; Luo L.; Liu Y.; Zhang C.; Liu J.; Yang C.; Li Y.; He J.; Ye X.; Li Z.; Tan X.; Ge J.; Cao W.; Wang S.; Zhang X.; Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia (r\/r T-ALL). J Clin Oncol  2020,38(15_suppl),3013","journal-title":"J Clin Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2023-178723","volume":"142","author":"Ghobadi A.","year":"2023","unstructured":"Ghobadi A.; Aldoss I.; Maude S.L.; Bhojwani D.; Wayne A.S.; Bajel A.; Faramand R.; Mattison R.J.; Dholaria B.; Rettig M.P.; Jacobs K.; Bakkacha O.; Muth J.; Pannunzio A.; Ramsey B.; McNulty E.; Cooper M.L.; Davidson-Moncada J.; DiPersio J.F.; Phase 1\/2 dose-escalation\/dose-expansion study of anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (T-ALL\/LBL). Blood  2023,142(Suppl. 1),770","journal-title":"Blood"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1182\/blood-2022-165733","volume":"140","author":"Zhang X.","year":"2022","unstructured":"Zhang X.; Zhou Y.; Yang J.; Li J.; Qiu L.; Ge W.; Pei B.; Chen J.; Han L.; Ren J.; Lu P.; A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood  2022,140(Suppl. 1),4566-4567","journal-title":"Blood"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1200\/JCO.2022.40.16_suppl.7035","volume":"40","author":"Zhao L.","year":"2022","unstructured":"Zhao L.; Pan J.; Tang K.; Tan Y.; Deng B.; Ling Z.; Song W.; Chang A.H.; Feng X.; Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia\/lymphoma. J Clin Oncol  2022,40(16_suppl),7035","journal-title":"J Clin Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/01.HS9.0000847808.59949.f6","volume":"6","author":"Hu K.","year":"2022","unstructured":"Hu K.; Yang F.; Shi H.; Liu R.; Zheng P.; Feng S.; Guo Y.; P1236: Efficacy and toxicity for CD7 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory T-cell lymphoma. HemaSphere  2022,6,1121-1122","journal-title":"HemaSphere"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2021-146425","volume":"138","author":"Zhang X.","year":"2021","unstructured":"Zhang X.; Yang J.; Li J.; Shi Y.; Su Y.; Liu Y.; Ba M.; Wu Y.; Li W.; Li J.; Lu P.; First-in-human clinical study of a novel CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory\/relapsed mixed phenotype acute leukemia (MPAL). Blood  2021,138(Suppl. 1),1741","journal-title":"Blood"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1182\/blood-2023-184370","volume":"142","author":"Cheng J.","year":"2023","unstructured":"Cheng J.; Wang J.; Mao X.; Mu W.; Sun S.; Zhou X.; Huang L.; Phase 1 dose escalation study of the anti-CD7 CAR-T therapy in relapsed\/refractory T-cell acute leukemia and lymphoblastic lymphoma. Blood  2023,142(Suppl. 1),6863","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"Zhang M.","year":"2022","unstructured":"Zhang M.; Chen D.; Fu X.; Meng H.; Nan F.; Sun Z.; Yu H.; Zhang L.; Li L.; Li X.; Wang X.; Wang M.; You F.; Li Z.; Chang Y.; Zhou Z.; Yan J.; Li J.; Wu X.; Wang Y.; Wang Y.; Xiang S.; Chen Y.; Pan G.; Xu H.; Zhang B.; Yang L.; Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin Cancer Res  2022,28(13),2830-2843","journal-title":"Clin Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","volume":"13","author":"Zhang Y.","year":"2023","unstructured":"Zhang Y.; Li C.; Du M.; Jiang H.; Luo W.; Tang L.; Kang Y.; Xu J.; Wu Z.; Wang X.; Huang Z.; Zhang Y.; Wu D.; Chang A.H.; Hu Y.; Mei H.; Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J  2023,13(1),61","journal-title":"Blood Cancer J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1080\/10428194.2023.2243357","volume":"64","author":"Becerril-Rico J.","year":"2023","unstructured":"Becerril-Rico J.; Delgado-Montes Y.A.; Ortiz-S\u00e1nchez E.; Differences in efficacy and safety among CAR-Ts anti-CD19\/CD22, anti-CD19, and anti-CD22, in adult patients with relapse\/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review. Leuk Lymphoma  2023,64(11),1822-1831","journal-title":"Leuk Lymphoma"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e149819","DOI":"10.1172\/jci.insight.149819","volume":"6","author":"Kim M.Y.","year":"2021","unstructured":"Kim M.Y.; Cooper M.L.; Jacobs M.T.; Ritchey J.K.; Hollaway J.; Fehniger T.A.; DiPersio J.F.; CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. JCI Insight  2021,6(16),e149819","journal-title":"JCI Insight"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/intimm\/9.12.1875","volume":"9","author":"Bonilla F.","year":"1997","unstructured":"Bonilla F.; Kokron C.M.; Swinton P.; Geha R.S.; Targeted gene disruption of murine CD7. Int Immunol  1997,9(12),1875-1883","journal-title":"Int Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.4049\/jimmunol.160.12.5749","volume":"160","author":"Lee D.M.","year":"1998","unstructured":"Lee D.M.; Staats H.F.; Sundy J.S.; Patel D.D.; Sempowski G.D.; Scearce R.M.; Jones D.M.; Haynes B.F.; Immunologic characterization of CD7-deficient mice. J Immunol  1998,160(12),5749-5756","journal-title":"J Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"Wudhikarn K.","year":"2022","unstructured":"Wudhikarn K.; Perales M.A.; Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant  2022,57(10),1477-1488","journal-title":"Bone Marrow Transplant"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/j.clml.2020.12.010","volume":"21","author":"Aamir S.","year":"2021","unstructured":"Aamir S.; Anwar M.Y.; Khalid F.; Khan S.I.; Ali M.A.; Khattak Z.E.; Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed\/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes. Clin Lymphoma Myeloma Leuk  2021,21(4),e334-e347","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206321313240820101412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233378\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206321313240820101412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T07:20:45Z","timestamp":1733728845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233378\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715206321313240820101412","relation":{},"ISSN":["1871-5206"],"issn-type":[{"type":"print","value":"1871-5206"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}